A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

NCT06585241 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

1144

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL: mRNA-1273 Variant-containing Formulation

Sponsor

ModernaTX, Inc.